Stock AnalizVeracyte, Inc. VCYT
Medical Specialities · IPO 2013 · data as of November 13, 2026
Veracyte, Inc. (VCYT) is a healthcare company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $582M and net income of $127M, a net margin of 21.8%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 15.8, a price to free cash flow of 12.1, 5-year revenue growth of 34% a year, a 5-year average ROIC of -2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 41% below the current price.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Pays a dividend
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $582M | $517M | $446M | $361M | $297M | $220M | $117M | $120M | $92M | $72M | $65M |
| Net income | $127M | $66M | $24M | -$74M | -$37M | -$76M | -$35M | -$13M | -$23M | -$31M | -$31M |
| Free cash flow | $162M | $127M | $64M | $34M | -$1M | -$37M | -$13M | -$6M | -$15M | -$26M | -$32M |
| EPS (diluted) | $1.54 | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 | $-0.66 | $-0.27 | $-0.62 | $-0.91 | $-1.09 |
| Net margin | 21.8% | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | -29.7% | -10.5% | -25.0% | -43.1% | -48.2% |
| ROIC | — | 4.2% | 1.2% | -7.9% | -3.0% | -6.8% | -8.2% | -6.0% | -21.2% | -42.7% | -34.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $45.11, 85% above the current price; targets range from $30.00 to $65.00; the consensus rating is “Buy”; expected EPS is $1.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Veracyte’s P/E ratio?
About 15.8, based on the last twelve months of diluted earnings per share (forward P/E about 16.2).
Is Veracyte stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 41% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Veracyte pay a dividend?
Not currently.
Is Veracyte a good stock to buy?
We do not give buy or sell advice. Veracyte scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.